BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Interest Expense
Cost of servicing the company's debt during the period.
BioAge Labs, Inc.NASDAQ: BIOA
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense declines year over year
Q1 FY2026 interest expense of $39K fell 84.7% year over year, behind the -65.8% change in trailing-twelve-month interest expense. Sequentially, it fell 57.6% from the prior quarter. Over 3 fiscal years it compounded at +42.5% a year.
Context
- Interest expense amounted to 7.7% of revenue in FY2025.
- Interest expense increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -84.7% toward the trailing-twelve-month pace of -65.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 697K USD
- Year-over-year change
- -70.6%
- 3-year CAGR
- +42.5%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 697K | -70.6% |
| FY2024 | 2024-12-31 | 2.37M | -69.6% |
| FY2023 | 2023-12-31 | 7.79M | +3134.0% |
| FY2022 | 2022-12-31 | 241K | — |
Interest Expense vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -65.8% is the 7th highest of 8, against a peer median of +0.6%.
- Interest expense amounts to 4.7% of revenue for BIOA, versus a peer median of 8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$40.92M CAD | -45.1% | -32.9% | 13.1% | |
| LTM Mar 2026 | $22.88M USD | — | +12.0% | 16.9% | |
| LTM Mar 2026 | $10.52M USD | +0.6% | +22.0% | 521.9% | |
| LTM Mar 2026 | CA$5.82M CAD | -30.9% | -64.2% | 1.9% | |
| LTM Mar 2026 | $2.35M USD | +125.1% | — | — | |
| LTM Mar 2026 | $1.23M USD | +270.1% | — | — | |
| LTM Mar 2026 | $785K USD | +14.4% | — | 1.9% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $481K USD | -65.8% | +42.5% | 4.7% |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | -$1.14M USD | -151.6% | — | 3.0% | |
| Peer median (excluding BIOA) | — | +0.6% | -10.4% | 8.0% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 9M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 9M |
| Gross Margin | — | — | — | 100.0% |
| Research & Development | 30.52M | 33.89M | 59.04M | 73.97M |
| Selling, General & Admin | 9.45M | 14.51M | 19.16M | 27.81M |
| Operating Expenses | 39.97M | 48.4M | 78.19M | 101.78M |
| Depreciation & Amortization | 129K | 162K | 167K | 213K |
| EBITDA | (39.35M) | (55.9M) | (68.58M) | (79.7M) |
| EBITDA Margin | — | — | — | -886.0% |
| Operating Income | (39.97M) | (48.4M) | (78.19M) | (92.78M) |
| Operating Margin | — | — | — | -1031.5% |
| Interest Income | 465K | 2.43M | 9.63M | 13.09M |
| Interest Expense | 241K | 7.79M | 2.37M | 697K |
| Other Income / Expenses | 247K | (15.45M) | 7.09M | 12.18M |
| Income Before Tax | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Pre-Tax Margin | — | — | — | -896.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Net Margin | — | — | — | -896.1% |
| EPS (Basic) | (1.16) | (1.87) | (1.98) | (2.24) |
| EPS (Diluted) | (1.16) | (1.87) | (1.98) | (2.24) |
| Weighted Avg Shares | 34.17M | 34.2M | 35.85M | 35.93M |
| Weighted Avg Shares (Diluted) | 34.17M | 34.2M | 35.85M | 35.93M |
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.